Elevation Partners with Synaffix in $368M Deal to Advance HER3 ADC Development

Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform technologies. This collaboration aims to create a highly effective and safer therapy for HER3-positive solid tumors. With up to $368 million in milestone payments, this partnership highlights the transformative potential of ADCs in precision oncology and patient care.

Cutting-Edge Technology Integration

Synaffix provides Elevation Oncology with global access to its clinical-stage, site-specific ADC technology platform, including GlycoConnect® antibody conjugation, HydraSpace® polar spacer, and the toxSYN® linker-payload SYNstatin E™. These advanced technologies enable the creation of a differentiated HER3 ADC candidate with enhanced efficacy and tolerability, holding the potential to set a new benchmark in oncology therapeutics.

David Dornan, Chief Scientific Officer of Elevation Oncology, emphasized the significance of this collaboration, stating, “Our partnership with Synaffix enables us to build a HER3 ADC candidate with best-in-class potential, which leverages Synaffix's state-of-the-art site-specific conjugation and differentiated linker-payload for a potentially improved safety and efficacy profile. We look forward to advancing our pipeline as we work toward transforming the care and treatment of patients living with solid tumors that express HER3.”

Strategic and Financial Framework

Under the agreement terms, Synaffix will receive up to $368 million, contingent on achieving specific clinical, regulatory, and commercial milestones. Additionally, Elevation Oncology will handle research, development, and commercialization, while Synaffix will manage manufacturing components tied to its proprietary platform.

Peter van de Sande, Head of Synaffix, shared his excitement about the partnership: “As a dedicated partner in the ADC space, Synaffix is excited to collaborate with Elevation Oncology to push the boundary of ADC innovation. With our state-of-the-art ADC technology platform and established supply chain, Elevation is well-positioned to accelerate the development of its differentiated HER3 ADC.”

Implications for Cancer Care

HER3, a receptor in the ErbB family, is associated with resistance to conventional therapies in various solid tumors, making it a critical target in oncology research. Elevation Oncology’s EO-1022 aims to address this challenge by combining Synaffix’s technology with a HER3-targeting antibody to create a more effective and safer therapy.